Waters Corp

Waters Corporation has reported positive financial results for the second quarter, exceeding street estimates and raising its full-year 2025 guidance.

Waters Corporation’s stock price has demonstrated stability, with a premium valuation reflecting investors’ confidence in its future growth prospects.

Waters Corp has announced a strategic partnership with Becton Dickinson, merging a Becton Dickinson unit with Waters’ Biosciences & Diagnostic Solutions division to create a leading bioscience and diagnostics company.

Waters Corp has announced a $17.5 billion partnership with Becton Dickinson, set to create a medical testing giant with a projected $40 billion addressable market.

Waters Corporation has introduced BioResolve Protein A Affinity Columns, a game-changing innovation that accelerates the development of lifesaving therapies by streamlining upstream bioprocessing and improving sensitivity.